Merck & Co., Inc. (MRK) Earnings Call Transcript & Summary
April 29, 2021
Earnings Call Speaker Segments
Peter Dannenbaum
executiveThanks, Lara. Good morning, everyone, and welcome to the conference call for Merck's first quarter of 2021. Joining me today are Ken Frazier, who serves as our Chairman and Chief Executive Officer, along with Rob Davis, our President; Dr. Dean Li, President of Merck Research Laboratories; Frank Clyburn, President of Human Health; and Caroline Litchfield, our Chief Financial Officer. Before we begin, there are a few things I want to flag. In our GAAP results, you'll notice certain items, including charges tied to acquisitions, costs from restructuring, and some other items as well. Keep in mind that these have been excluded from our non-GAAP results, and a reconciliation is provided in the press release. I'd also like to remind everyone that certain statements made on today's call might be viewed as forward-looking statements under the Safe Harbor provision of the U.S. Private Securities Litigation Reform Act of 1995. Statements of that kind reflect the current beliefs of Merck's management and carry significant risks and uncertainties. Should our underlying assumptions turn out to be inaccurate, or should uncertainties come to pass, actual results could differ materially from what those forward-looking statements set forth. In our SEC filings, including Item One A in the 2020 10-K, certain risk factors and cautionary statements are identified that could lead the company's actual results to differ materially from those projected in any forward-looking statements we make this morning. Merck has no obligation to publicly update any forward-looking statements. Our SEC filings, today's earnings release, and an investor presentation highlighting our results are all available on merck.com. With that, I'll hand the call over to Kenneth Frazier.
Kenneth Frazier
executiveThanks, Peter. Good morning, everyone, and I appreciate your presence on today's call. The year 2021 represents Merck's 130th, giving us a chance to look back at our organization's legacy of delivering breakthrough innovations that have reshaped medical paradigms in numerous therapeutic fields. At present, we are positioned strongly to secure lasting success going forward, thanks to our exceptionally skilled workforce, our scientific know-how, our encouraging pipeline, and our fiscal and operational resilience. We are likewise implementing the appropriate measures to transform Merck's operating model so the company is best situated for what lies ahead as the industry environment keeps shifting. The forthcoming separation of Organon will sharpen our emphasis on innovation and on our primary growth drivers even more, and that will make possible essential funding for pioneering science. The leadership transitions at Merck have been carefully mapped out, and smooth succession is already progressing well. Every one of our recently named leaders possesses a demonstrated history of achievement and personifies the company's mission. I have every confidence that this team, under Rob's direction, is more than prepared to assume control and guide this company forward. Turning to the quarter's results, although the pandemic went on affecting both patient access and the capacity of healthcare providers to treat, we turned in a strong performance, particularly when you factor in the large share of physician-administered products within our portfolio, most notably our vaccine. On the subject of the pandemic, Merck stays dedicated to advancing molnupiravir as a significant possible therapy for COVID-19, and we take pride in collaborating with Johnson & Johnson to produce their vaccine. This will be my last earnings call in the CEO position before I step down from that role on June 30. I want you to know that I value the useful and constructive feedback all of you have offered me throughout the years, and I anticipate serving as Executive Chairman of the Board of Directors and functioning in an advisory capacity, and above all, watching Merck reach still greater heights. Having said that, I'll hand the call over to Rob Davis.
Robert M. Davis
executiveAppreciate that, Ken. Morning, everybody. Ken is holding his 42nd — and last — earnings call in the CEO seat. Everyone here at Merck wants to express our gratitude for everything he has done for this organization, for the scientific community, and for our customers and patients worldwide. We're wishing him a great deal of success and happiness as he begins the next chapter following an outstanding tenure leading Merck. We're eager for his ongoing guidance in his new capacity as our executive chairman. As I step into the CEO position, one thing I want to address right away is making certain our seasoned and empowered leadership group keeps extending the solid base and good momentum that exists throughout the company. With that in mind, I'm delighted to have Caroline Litchfield join the executive committee as our incoming Chief Financial Officer. Most recently, Caroline Litchfield was Merck's treasurer, and before that she led finance for our Human Health business. Her 30-year career at Merck has been distinguished, with finance positions spanning multiple regions and businesses, and she is extremely well-suited to run our finance organization and offer strategic perspective as part of our senior leadership team. I'm equally pleased that Frank Clyburn's responsibilities have grown to president of our Human Health business, covering our commercial and marketing operations alike. Over the last decade, Frank Clyburn's vision and leadership have been essential forces behind Merck's achievements, especially as we expanded our oncology business and delivered remarkable commercial results. Beyond that, I've been collaborating closely with Dean Li to keep the link between commercial and research operations robust. Research and development is Merck's lifeblood, and Dean along with his team are entirely dedicated to advancing scientific innovation and directing resources efficiently toward our most promising pipeline opportunities. Although our portfolio keeps experiencing pandemic-related effects, we trust that underlying demand for our products is still solid, and we're hopeful that a more typical environment is starting to appear. This quarter we completed key business development deals, and we've achieved significant pipeline progress. Frank, Caroline, and Dean will address that shortly, but first let me update you on where my attention has been throughout this transition. I've devoted considerable time to the leadership team and numerous others throughout the company to make sure communication stays open and we have a clear route to sustained success. As president, I'm spending my time hearing from people across the company, which helps me refine my own thinking about where we're headed strategically and start setting the priorities that will get us there. In the near term, though, my attention is on making sure we keep delivering against the major commercial and development opportunities in front of us so we capture the substantial growth we're capable of, and at the same time I'm making sure we take the steps required to reshape how we operate so we're positioned as well as possible for the healthcare landscape that's changing over the long haul. Along those lines, our focus stays on getting our late-stage pipeline delivered and moving programs forward from an early-stage pipeline that's strong and expanding; we'll also keep adding to these efforts through business development done internally, aimed at bringing in meaningful assets. Two good illustrations of deals we closed this quarter, each with considerable potential to create value, are the purchase of Pandion along with its immunology asset that could prove foundational, and the HIV partnership with Gilead Sciences. And last, we'll keep doing what's needed to help turn Merck into a company that's leaner and more agile and focused, an example being the Organon spin-off that's coming up. On Monday we're looking forward to an investor day, where Organon's entire leadership team will walk through its strategy and the opportunities it has to grow. Our expectation is that the spin-off closes on June 2, and that the new stock starts trading on June 3. To wrap up, our confidence remains strong that the business is positioned well to grow robustly over the long term. The mission we have will keep being what propels this company and gives us purpose. Specifically, we'll stay concentrated on scientific innovation that targets substantial unmet medical needs and betters the lives of the patients we serve. It's my firm belief that putting patients at the center of all we do is what generates the greatest value for every stakeholder, our shareholders included. With that, I'll hand the call over to Frank.
Frank Clyburn
executiveThank you, Rob. Good morning, everyone. I'm thrilled to take on a broader role as President of Human Health and to continue building upon the commercial momentum we have generated. Our confidence in the fundamental demand for our main products remains very high, and for the entire year, we still expect robust growth for our business. Having said that, the fundamental strength of our Human Health business took a hit during this quarter because of a rise in cases and further lockdowns around the world. These challenges partly represented a continuation of diminished patient access to physicians' offices and wellness visits that were below typical levels, and they were felt more acutely early in the quarter because of the surge in infections that took place. The distribution of COVID-19 vaccines and guidance against administering them alongside other shots have likewise affected portions of our vaccine business. As a reminder, approximately 70% of our pharmaceutical revenue comes from products that physicians administer. It's also important to remember that our year-over-year growth faced a tough comparison because of the exceptionally strong first quarter we delivered in 2020, plus variability between quarters in GARDASIL sales. Because of all these elements, our sales came in roughly level with the prior year, or down 3% when you strip out the favorable effect of foreign exchange. I'll take you through some of what we expect for future trends shortly, but first, let me cover how our key brands performed in the first quarter. My remarks will be presented on an ex-exchange basis. Within oncology, KEYTRUDA sales rose 16% to $3.9 billion, driven by sustained strong demand. In the U.S., KEYTRUDA keeps its leading position in lung cancer, including securing eight of 10 eligible new patients, and it is gaining from robust use across every major tumor type, such as renal cell carcinoma, bladder, adjuvant melanoma, our MSI-H indication, triple-negative breast cancer, and also the cutaneous squamous cell cancer and renal cell carcinoma. Lynparza increased 51% during the quarter, helped by continuing launches and wider reimbursement that keep reinforcing its standing as the top PARP inhibitor. Lenvima came in essentially flat, which mirrors competitive newcomers in hepatocellular carcinoma and a one-time accrual tied to the recent NRDL listing for hepatocellular carcinoma in China. Lower than usual wellness visits, especially in the U.S., along with challenges stemming from the rollout of COVID vaccines among adults, weighed on our vaccine portfolio. GARDASIL sales were hurt by the timing of shipments to China a year ago and the timing of U.S. public sector purchases in both periods, as well as pandemic effects in the United States and in Europe. PNEUMOVAX sales fell because of a difficult year-over-year comparison, given robust demand for pneumococcal vaccination when the pandemic began last year, and the effect of CDC COVID vaccine co-administration guidelines, partly offset by stronger sales outside the U.S. Our hospital business kept bouncing back from pandemic effects. BRIDION sales climbed 11% year-over-year, fueled by wider usage and updated operating room protocols that permit more typical volumes of elective procedures. Our confidence in the fundamental demand for our innovative portfolio has not wavered, since these products deliver significant value to patients. As the COVID vaccines are rolled out effectively, we anticipate that patients will feel more at ease seeking medical attention without delay. Indeed, we take encouragement from the recovery patterns observed as the first quarter came to a close, with wellness visits during March in the U.S. exceeding levels seen before the pandemic. When it comes to oncology, an unfortunate decline in cancer screening rates has occurred since the pandemic began, leading to fewer diagnoses among patients and lower numbers of new patient starts for numerous oncology agents, especially in fields such as lung cancer. As COVID vaccines are deployed, particularly for older populations, among whom cancer incidence is greatest, and with more awareness efforts, we anticipate that screenings and diagnoses will quickly revert to typical levels. For KEYTRUDA, we anticipate ongoing robust expansion, owing to its leading status in numerous existing indications. The recent approval for esophageal cancer has us enthusiastic, as do possible further indications in renal cell carcinoma, such as in combination with Lenvima and as a monotherapy in the adjuvant setting. Regarding vaccines, the recent uptick in wellness visits is a positive sign, along with awareness initiatives that boost the likelihood of catch-up vaccinations throughout the portfolio as patient access gets better. We'll keep an eye on how GARDASIL is affected, particularly during the back-to-school period. That being said, within the United States, to facilitate a secure return to in-person education in the fall, considerable focus is being placed on speeding up adolescents' doctor appointments so they can catch up on missed routine vaccinations and arrange new ones in coordination with the COVID vaccine rollout for this group. We will likewise track numerous markets outside the U.S. where COVID vaccination rates have been slower compared to the United States, and where fresh lockdowns have occurred that are anticipated to affect physician well visits and school-based vaccination initiatives. On the whole, though, we think there is robust worldwide demand for GARDASIL, especially in ex-US markets such as China. This year, we have observed enhancements in our manufacturing capacity, which will additionally help our sales. Because of this, we anticipate robust global expansion for GARDASIL in the current year. In closing, we have faith in the robustness and durability of our portfolio of innovative medicines and vaccines. We anticipate going back to more typical operations later in the year and achieving robust growth for the full year. There is fundamental patient demand for our products, and we think that after navigating the transient market shifts caused by the pandemic, our business will get back to a robust growth path far into the future. With that, I'll hand the call over to Caroline.
Caroline Litchfield
executiveThanks, Frank. Morning, everyone. It's a real privilege to step into the role of Chief Financial Officer at Merck & Co. and to collaborate more closely with such an outstanding group of leaders who share the deep commitment I feel toward this company's mission. I'm thrilled to take on leadership of the finance organization and to help keep Merck & Co. in a strong position to fund the science and innovation investments that our distinctive legacy depends on — a legacy of making a difference globally and generating value for patients and shareholders. Now, on to first quarter results. Company-wide revenues came in at $12.1 billion for the quarter, about flat versus a year ago on a nominal basis, or a decline of 1% once you strip out the favorable foreign exchange effect. Those results landed broadly in line with what we had initially anticipated. Frank walked through the fundamental strength of the Human Health business and the various ways the pandemic shaped the quarter, which we peg at roughly $600 million. Animal Health had an especially robust quarter, up 15% versus a year ago, powered by demand in both companion animal and livestock, which rose 24% and 9% respectively. Within companion animal, the increase came from greater worldwide demand for our parasiticides, chiefly the BRAVECTO product line, along with vaccine strength. Livestock performance mirrors rising demand internationally across ruminants, poultry, and swine, plus solid growth in our intelligence products. Let me now take you through the rest of our P&L, and I'll be speaking on a non-GAAP basis. Gross margin for the quarter was 75.7%, down 0.8%, mostly because of elevated costs tied to COVID programs. Operating expenses rose 10% versus a year ago, reaching $4.9 billion, mainly from higher clinical development costs that include our COVID-19 program, more investment in the early-stage pipeline, and greater promotion spending behind key growth drivers. The effective tax rate came in at 14.1% for the quarter, 2.8% lower than a year ago, helped by favorable earnings mix and discrete items. All told, we earned $1.40 per share, which is a decline of 7%. Now to our revised 2021 guidance for Merck, including Organon. First quarter revenues were broadly in line with what we expected. We still anticipate revenues between $51.8 billion and $53.8 billion, which represents growth of 8% to 12% compared with 2020. The fundamental strength of our growth pillars gives us confidence that revenues will accelerate strongly through the rest of the year, even with a somewhat less favorable foreign exchange impact and a larger projected pandemic impact. Revenue from the possible launch of molnupiravir is not included in our guidance. Our growth margin is now projected at approximately 76%, a bit below earlier guidance due to COVID-19's impact. We now anticipate operating expenses growing at a mid to high single-digit rate, slower than our previous guidance, largely from disciplined management of SG&A expenses. When you strip out the effects of COVID-19, we'd anticipate operating expenses rising at a rate nearer to the mid-single digits. Guidance on other income and expense, the tax rate, and shares outstanding stays the same as what we gave last quarter. Putting it all together, our expectation for non-GAAP EPS remains $6.48 to $6.68, which represents growth of 12% to 15%. Inside that range there's a favorable currency effect of under 3%. Turning to Organon, looking at it pro forma — as if it had run as a standalone business across the entire year — we now see Organon delivering revenues of $6.1 billion to $6.4 billion. If the spin-off closes as planned, Merck's full-year revenues from continuing operations are anticipated to land between $45.8 billion and $47.8 billion. We still anticipate roughly $1.5 billion of operating efficiencies coming from the spin across three years, and that figure includes $500 million during 2021. Because Organon's products carry higher profitability than Merck overall, we foresee Merck's operating margin from continuing operations dipping slightly in 2021 relative to the level it would have reached had there been no spin-off, then speeding up and exceeding that no-spin-off level within 12 to 24 months, and surpassing 42% by 2024; our confidence is unchanged that this transaction will help the patients served by both Merck and Organon and generate shareholder value. Merck's revenue and earnings growth rates should be stronger once the spin-off is done. Thanks to Merck's quicker growth, the operating efficiencies we anticipate realizing from the spin, and the faster growth we foresee for Organon's products under an independent structure, we project the two companies' combined EPS to exceed the no-spin scenario within 12 to 24 months. At the closing of the Organon spin-off, a special tax-free dividend of $9 billion is expected to come our way, and our hope is to put it to work in strategic business development that enhances value; should no meaningful business development materialize, our plan is to give cash back to shareholders via share repurchases. As ever, we're dedicated to making sure we invest appropriately in the business — both to back our key brands and to push forward the innovation advancing through our pipeline; over time, we'll aim to raise our dividend payout ratio. To wrap up, I'm thrilled to begin my journey as CFO and to step in at a moment when our company's financial position is so strong; our confidence in the business outlook is unchanged, and I'm eager to play my part in keeping Merck financially well-positioned to deliver sustainable value to patients and shareholders. With that, I'd like to hand the call over to Dean.
Dean Li
executiveThank you, Caroline. In the remarks I'll make today, I'll go over important regulatory milestones and clinical updates, starting with oncology and then moving to the rest of our pipeline, and I'll wrap up with a look at recent business development activity. During the first quarter, the FDA accepted and gave priority review to a new drug application for belzutifan, the investigational HIF-2α inhibitor we picked up from Peloton, for treating certain patients who have von Hippel-Lindau disease-associated renal cell carcinoma, with a September PDUFA date. We're looking at this asset more closely through three Phase III studies in RCC that are ongoing. We kicked off a Phase III study of vibostolimab, our investigational anti-TIGIT antibody, given together with KEYTRUDA in patients with non-small cell lung cancer whose tumors express PD-L1. That's one of a number of co-formulated assets from our oncology portfolio that we expect to move forward this year, building on what KEYTRUDA has achieved. Now to FDA approvals: KEYTRUDA won an indication, combined with chemotherapy, for treating certain patients with advanced esophageal carcinoma, irrespective of PD-L1 expression, supported by KEYNOTE-590. That makes the 11 approved indication backed by a clinical study showing an overall survival benefit. Beyond the United States, the European Commission cleared new indications for KEYTRUDA in adult and pediatric patients with relapsed or refractory classical Hodgkin lymphoma, drawing on findings from KEYNOTE-204, and in patients with microsatellite instability-high or mismatch repair-deficient previously untreated colorectal cancer, drawing on KEYNOTE-177. Earlier this month, we announced that after an interim analysis, KEYNOTE-564, our phase III study of KEYTRUDA as an adjuvant monotherapy in patients with renal cell carcinoma, hit its primary endpoint of disease-free survival. We'll share these data with regulatory authorities and present them at ASCO. That gives us another proof point for KEYTRUDA's benefit in earlier lines of therapy, where we anticipate additional readouts in several other tumor types this year, and it also backs our broad development program in patients with renal cell carcinoma. We recently got a positive opinion from the CHMP for Q6W dosing across KEYTRUDA combination regimens for patients in the EU, which adds to the six-week dosing schedule already approved in monotherapy indications. At the AACR annual meeting, initial results from KEYNOTE-555, which evaluated a subcutaneous formulation of KEYTRUDA in patients with metastatic melanoma, were presented. We're continuing to study this new formulation as well as other innovative modes of administration and dosing intended to deliver increased benefit and access for patients. Together with our partners at Eisai, we presented potentially practice-changing data showing the benefit of KEYTRUDA plus Lenvima in the first-line treatment of patients with advanced renal cell carcinoma and in second-line advanced endometrial carcinoma, based on results from KEYNOTE-581 and KEYNOTE-775, respectively. These studies showed statistically significant improvements across primary and secondary endpoints, and we look forward to working with global regulatory authorities on these filings. Back in February, together with AstraZeneca, we shared news that an interim analysis had shown the phase III OlympiA trial — which is examining Lynparza as maintenance therapy in the adjuvant setting for specific patients with germline BRCA-mutated, high-risk, HER2-negative, early-stage breast cancer — had gone past the superiority boundary on its primary endpoint of invasive disease-free survival compared with placebo. The study is still assessing the dual primary endpoints of overall survival and distant disease-free survival, and those findings are going to be presented at ASCO. We're also happy about the positive result from yesterday's Oncologic Drugs Advisory Committee review of our first-line advanced bladder cancer indication, and about the acknowledgment of the efficacy and safety KEYTRUDA has shown in clinical trials. We're eager to keep talking with the committee about other accelerated approvals currently under review. Last month, we let everyone know we had decided to voluntarily pull an indication for KEYTRUDA covering third-line treatment of patients with metastatic small cell lung cancer. As we announced, the FDA sent us a complete response letter regarding a supplemental biologics application for KEYTRUDA for neoadjuvant and adjuvant treatment of patients with triple-negative breast cancer, based on KEYNOTE-522. We expect the next interim analysis from that trial during the third quarter of 2021, and we're eager to continue our discussions with the FDA. Now, moving on to our broader pipeline. On molnupiravir, working alongside our partners at Ridgeback Biotherapeutics, we reported interim results from the dose-finding portion of Phase II/III studies covering both outpatients and hospitalized patients. Having reviewed the data, we've chosen to move ahead into Phase III among outpatients, with enrollment concentrated on higher-risk populations. We're going to assess molnupiravir as a post-exposure prophylactic option in a study that begins later this year. As we've mentioned before, we've decided to stop developing MK-7110 for COVID-19 and intend to concentrate our pandemic-related efforts on pushing molnupiravir forward and on manufacturing Johnson & Johnson's COVID-19 vaccine. In HIV, we're still seeing solid progress in our development program for islatravir, our potentially first-in-class nucleoside reverse transcriptase translocation inhibitor. Data shared at last month's CROI meeting backs the potential of islatravir in long-acting dosing regimens for both treatment and PrEP settings. Worth highlighting was early data supporting the possibility that subdermal islatravir implants could keep drug concentrations above the target pharmacokinetic threshold for at least one year. We're glad to build on our legacy of innovation in HIV through our collaboration with Gilead Sciences to co-develop and co-commercialize islatravir and lenacapavir. Each brings unique properties that we think could make it possible to create effective long-acting oral and injectable regimens, delivering important new treatment options and tackling the remaining unmet need for people living with HIV. Our pneumococcal vaccine, V114, is still on track for possible FDA approval for adults in July, along with a readout of pediatric data and associated filings by year-end. V114 leads a group of encouraging pneumococcal vaccine prospects, and among them is V116, aimed at adults, for which we anticipate data from our phase I/II trial before this year ends. We also shared that the FDA has accepted our new drug application for gefapixant, a P2X3 inhibitor that could be first-in-class, intended for adults suffering from refractory and unexplained chronic cough. A ruling should come in December. An advisory committee meeting will be held concerning this application; we keep seeking business development in the most thrilling scientific fields. Through buying Pandion Therapeutics, we are broadening and enhancing our in-house pipeline of candidates that target autoimmune diseases. Pandion's top IL-2 candidate could be substantially differentiated thanks to its high selectivity, and we intend to launch the phase I-B/II trial during this year; our pipeline continues to advance strongly. Such momentum stems from the dedication and enthusiasm of the scientists in our Research Laboratories working to deliver life-saving medicines and vaccines to patients everywhere. I'll now hand the call back over to Peter.
Peter Dannenbaum
executiveThanks, Dean. Lara, let’s take questions now. I want to wrap up today’s call at 9:00. Please, those asking questions, keep it to a single question.
Terence Flynn
analystGreat, and I appreciate you taking my question. I was curious about the KEYNOTE-564 trial in RCC — do you think you'll be in a position to submit based on disease-free survival, or will the FDA insist on survival data as well? On the commercial side, this may be one for Frank. My understanding is that the present treatment rate in the neoadjuvant setting for RCC sits at roughly 10% to 15%. Could you share any perspective on how much further that number could climb assuming KEYTRUDA gets approved in this setting? Thank you.
Dean Li
executiveI'll take the KEYNOTE-564 question. As far as what the regulatory agencies are going to accept, we will certainly be holding discussions with them. The endpoint we reported is a registrational one, and we're hopeful about having additional conversations with the FDA. Obviously, we are moving the studies forward to address the other endpoints you mentioned, including overall survival.
Frank Clyburn
executiveYes, Terence — Frank here. Regarding that opportunity: most renal cell carcinoma patients show up in the adjuvant setting, while the rest are in the metastatic setting. Roughly 75% arrive at the early stage. That's a really strong opportunity in our view. If you examine our study, as we identify and assess patients who qualify, the adjuvant opportunity and the metastatic opportunity come out in roughly equal terms; should approval come through, we're quite enthusiastic about what lies ahead.
Peter Dannenbaum
executiveThanks, Terence. Let's take the next question.
Umer Raffat
analystI appreciate you taking my question. If I could, I'd like to zero in on the molnupiravir outpatient trial. There are a few aspects to this. First, within the phase II portion of this trial, what share involved older adults above 60? And then for phase III, what proportion of participants would need to be older to reach the event count you're targeting within the timeframe you have in mind? I understand the endpoint centers on hospitalizations and deaths, but the sites for this trial are mostly in the U.S. and Europe, where vaccination is happening at a high rate. Would you be open to perhaps bringing in sites such as India and elsewhere, where hospitalization rates are elevated? Thank you very much.
Dean Li
executiveI'll address that. I really appreciate the question; our confidence in the molnupiravir program is very high. As you described, we're moving the outpatient piece forward. I should add that we're ready to launch the phase III portion of that outpatient study very soon. As you're aware, this trial is global, with a recruitment approach centered on regions where we're seeing vaccination rates that are, unfortunately, low. We have a presence in Africa and in South America. Those sites are going to matter a great deal. We expect contributions from over 100 sites. This study spans the globe. Regarding what you asked about India, we've signed a voluntary license agreement with five generic manufacturers in India to broaden worldwide access to molnupiravir. Right now, we aren't expanding our clinical trial for MOVe-OUT into India. Last, I'd note that our clinical safety and virologic data provide strong confidence for evaluating molnupiravir, both in the MOVe-OUT study and for post-exposure prophylaxis in a study that begins later this year.
Peter Dannenbaum
executiveThanks, Umer. Let's take the next question.
Chris Schott
analystGreat, thank you very much. My question about BD has two parts. Through the Organon spin, you'll be receiving $9 billion. Clearly, this company produces substantial cash flow. If we keep up the present rate of these tuck-in kinds of acquisitions, at some point it appears Merck would become over-capitalized. When you examine the BD landscape, do you have confidence that actionable opportunities exist for putting this capital to work in transactions? Do we reach a stage where further capital return to shareholders needs consideration? While you're talking about the BD landscape, I'd be interested to hear what you're seeing out there — with the current environment, is it more likely that Merck does a bunch of smaller tuck-ins? Is there still an opportunity, in the near to intermediate term, to look at bigger or later stage acquisitions? Thanks so much.
Robert M. Davis
executiveChris, this is Rob. I'll give that a shot. Like you said, we're in a strong capital position, and we're expecting the $9 billion special dividend from the Organon spin-off. As Caroline mentioned during her prepared remarks, our intention is to allocate that capital toward business development as well as possibly repurchasing shares, but business development is clearly where our focus lies. In our view, that represents the best way to enhance value with our capital over the long term. Regarding whether sufficient assets exist in the market — we see plenty of opportunities. Our aim is to put that capital to work in BD, and seeing how things unfold will require more time. That's what we're aiming for. As to your second question, should we end up not using that capital for business development, building up excess cash or boosting our ratings isn't something I'm pursuing. That money would go back to our investors. On the second half of what you asked, about how big a target needs to be — our position has been consistent: any chance to bring in a substantial asset interests us. What makes something big isn't the price tag. It comes down to how complicated it is and how much it shakes up what we already do. From where we sit, no deal structure is off the table, and our balance sheet lets us pursue every one of them. Our view hasn't changed that our biggest contribution comes from assets still in their earlier phases, and that's behind many transactions we've completed; even so, we won't box ourselves in, and every possibility is getting a look.
Peter Dannenbaum
executiveThank you, Chris. Next question, please. Lara, next question, please.
Andrew Baum
analystThank you very much. I appreciate Kenneth Frazier's robust leadership across Merck as a whole. This one's for Robert M. Davis. When we talk with investors about Merck, the KEYTRUDA concentration risk comes up overwhelmingly, especially after Organon. My question: do you feel the market comes anywhere near capturing what the current pipeline products could generate — things like islatravir, belzutifan, sotatercept? Might Merck consider offering a combined projection for the pipeline as it stands, or, similar to what GSK has said it intends, provide 2030 guidance simply to give investors a clearer view of how Merck can handle the upcoming LOE tied to KEYTRUDA? Thanks so much.
Robert M. Davis
executiveYes. To address the first portion of what you asked directly, we hold a belief and confidence in the total worth of our pipeline — spanning what's in mid to late stage, and I can get more granular about that, plus the early stage — on top of what we view as ongoing chances to grow in oncology across neoadjuvant, adjuvant settings, combinations, and co-formulations. Considering all of it together, we keep believing — and I know that in time we'll need to prove it — but we keep believing that honestly, the Street underestimates what our pipeline can do. So even though we're quite conscious of a possible LOE for KEYTRUDA, the cliff doesn't look the same to us as it does to the Street. I believe we're positioned quite strongly with what we hold in-house to tackle a significant portion of that. Naturally, as we've stated, we know we must stay urgent about examining business development to keep bolstering it. I do believe a disconnect exists that in time, I'm certain we can show. On the matter of long-term guidance, I'd rather not commit to a particular stance right now regarding whether we'd ever pursue that. I can say that looking back, I agree with where Merck has stood — that approach can box you in and lead to choices that aren't always best for the long term. I suspect you won't see us offering 10-year guidance like what you've heard from other companies; time will tell. What matters to grasp, I think, is that I also recognize that in time, we'll need to reveal more about our portfolio in a measured manner. I hold our science in high regard, and I want to ensure we preserve the purity and integrity of that science — that's crucial. That's the essence of Merck. I likewise grasp that a balance exists in offering some understanding of the pipeline's contents to convey our confidence over time.
Peter Dannenbaum
executiveGreat. Thank you. Your next question, please, Lara.
Geoff Meacham
analystGood morning, everybody. I appreciate you taking the question. I just wanted to ask something further regarding molnupiravir. With the phase III data getting nearer, what's your thinking on the commercial side, if we assume there will be a rest-of-world skew, particularly considering how many cases there are in India? Looking at prophylaxis or the outpatient setting, how should patients be stratified, whether by viral load or by inflammation? I'm trying to figure out, as the pandemic evolves, how do you widen the pool of patients you could potentially treat? Thank you.
Dean Li
executiveExcellent question. This is Dean speaking. I'll offer a scientific perspective, then hand things over to Frank for a more commercial angle. Regarding molnupiravir, we will very soon begin the phase III trial in the outpatient setting. As mentioned in the earlier question, we are narrowing the inclusion criteria, cutting the permitted symptom duration for enrollment down to under five days, and we're aiming to enroll patients early in the disease course who face a high risk of poor outcomes. That covers age along with other risk factors like obesity and diabetes. We believe this will be essential for running a successful trial quickly. As for post-exposure prophylaxis, there are multiple ways to design such a trial, but to step back to a higher level, we believe this MOVE-OUT and the prophylaxis study will matter a great deal, not only for Merck but for the entire world. When you look at the varying levels of vaccination, some of it creating a variant reservoir even though it's extremely low, having a small molecule that's easy to give orally will be truly important globally. That's where our focus has been. I'll pass it to Frank now to address the commercial framework you raised.
Frank Clyburn
executiveRight, Dean Li, I believe you've addressed that thoroughly. Clearly, we'll need to observe how the endemic stage develops globally along with vaccination coverage, yet we regard this as a highly significant therapeutic — as Dean Li mentioned — having an oral small molecule alternative, particularly across numerous markets beyond the U.S. We possess considerable commercial expertise, a solid track record of delivering our therapeutics and vaccines to patients worldwide, and that's going to be a major priority for us; we view this as a truly important opportunity, especially in markets. Consider what's taking place not just in India, but also in low to middle-income nations, and consider what's taking place in Europe. Should we succeed, we believe this represents a really important opportunity for us moving forward.
Peter Dannenbaum
executiveAppreciate it, Geoff. Let's take the next one, Lara.
Ronny Gal
analystMorning, and thanks for fielding my question. I'd like to ask about messenger RNA technology. Could you share a bit about how you view folding mRNA vaccine tech into your operations, or whether you'd choose not to? Perhaps you could address GARDASIL specifically — does messenger RNA technology represent a threat to it? Are these platforms able to achieve the polyvalency required to create such vaccines? From a manufacturing cost standpoint at least, it looks like just a less expensive route to producing an equivalent vaccine.
Dean Li
executiveThanks for raising that — it's a great question. This is Dean. Let me lay out some context regarding mRNA. I want to stress again that Merck has maintained strong interest in mRNA as well as other nucleic acid technologies, and particularly in mRNA for vaccines; over the last 5 to 6 years, we at Merck have worked in partnership with Moderna on infectious disease vaccines and cancer vaccines. The way mRNA proved itself with COVID is remarkable, and speaking just for myself, it warrants respect and gratitude. Our interest persists in RNA and other nucleic acid-based technologies, viral-based platforms for vaccines among them. On your GARDASIL point specifically, I'd note that when there are multiple antigens of the sort you must deliver, I believe such platforms — protein-based ones — have a part to play. My sense is that numerous distinct platforms will be needed, tailored to the particular vaccine and the specific threat you're working to prevent. RNA and other nucleic acid-based technologies matter to us, viral-based platforms included, yet we likewise believe that, more broadly, additional protein subunit and other vaccine platforms will remain pertinent going forward.
Peter Dannenbaum
executiveThank you, Ronny. Next question, please, Lara.
Luisa Hector
analystThanks for taking my question. It concerns the PNEUMOVAX franchise, and I'm just wondering if we should essentially treat 2020 as the peak for PNEUMOVAX in particular, and then how ought we to view the competitive landscape here against your own pipeline suite, with V114 arriving very soon and then everything else behind it, versus the competitors? Thank you.
Frank Clyburn
executiveYeah. Regarding PNEUMOVAX, what I'd say is that if you look at what took place in Q1 of this year, we were down compared with the prior year, driven by the strong 2020 and the prioritization of pneumococcal vaccination; we do expect that, as you move through the remainder of 2021, pneumococcal vaccination will begin to be prioritized alongside flu vaccinations; we do expect that as you reach the back half of the year, you'll see PNEUMOVAX truly have a significant role to play. We've also noted that we are supply constrained when you look at PNEUMOVAX, particularly in certain markets of ours across the world. On the whole, we view it as a highly important product moving forward as we launch V114 and V116, and with the initial launch of V114, we still see PNEUMOVAX serving a very important function for pneumococcal disease going forward.
Peter Dannenbaum
executiveThanks, Luisa. Could we take the next question, please?
Geoff Meacham
analyststands to gain from. Thanks.
Robert M. Davis
executiveSure, when you take a look, and once more, to restate what you mentioned regarding our Monday call, it was entirely about constructing and helping clarify the growth narrative for Organon. When you consider Merck's position across recent years, we found ourselves fortunate to enjoy the advantages of what KEYTRUDA could accomplish, which demanded substantial spending from us to expand our oncology footprint, to fund the clinical trials in oncology. Then, more widely, when we consider everything underway in vaccines and now even with this molnupiravir in infectious diseases, the difficulty was that in numerous respects we needed to set priorities, and we chose to place lower priority on certain assets that reside in the Organon portfolio. A great many of those remain quite strong assets, and as you're aware, especially in women's health, a chance for genuine growth. My belief is that via focus, via being capable of truly steering their own capital allocation toward growing those businesses and the concentration they can deliver, they will speed up growth throughout not just the women's health business, but enthusiasm regarding what they possess in their biosimilars business. There are multiple areas, if you examine what they'll present next week, where I think they can reach a growth point. Much of it truly concerns focus and capital allocation in a manner we haven't managed, while on our end, we trust the spin and the simplification it delivers will let us pursue a great deal of, and I've mentioned this before, a great deal of the, as I've termed it, if you like, consider it the muscle, the fat that is scattered through the muscle in this company, because of the complexity of our structure that's accumulated over time; examining those areas lying between our divisions when we think about manufacturing and commercial, when we think about supply chain, every one of those presents chances for us to simplify and to remove unnecessary bureaucratic complexity; that simplification and focus will permit us to direct more resources toward our innovative portfolio and to generate quicker growth that Caroline discussed. My view is both businesses will grow more effectively as standalone businesses than they would as one combined entity. I have confidence in the story for each. Honestly, I'm thrilled about having a women's health-focused business right now, in where we stand as a society. I think there's a genuine chance for us to lead there, and that's what I look forward to seeing Organon accomplish.
Peter Dannenbaum
executiveThanks, Greg. Let's take the next question.
Seamus Fernandez
analystHi, and thank you. I'd like to revisit that 42% operating margin goal for 2024. Could you take us through the factors that help and the factors that hurt, specifically regarding the lighter royalty loads, and also what will be going on with the REMICADE SIMPONI contract at that moment? I realize that one carries a quite heavy royalty cost too. Our understanding was that a number of expirations land in that window and will lift margin substantially without needing to come from top-line leverage. On a different note, a question about the sort of business development that's taking place. I was hoping to understand better when you think we will truly begin to see some of these assorted smaller tuck-in transactions start to generate data that is, shall we say, phase II compelling, coming out of the earlier-stage deals, the ones that will actually fuel the next leg of growth. Does that fall into a comparable 2024, 2025 timeframe? The thing is, the visibility into the pipeline right now, as far as the street is concerned, is still, in my view, fairly modest. Thank you.
Peter Dannenbaum
executiveCaroline.
Caroline Litchfield
executiveSeamus, I appreciate that question. To begin, I'll address the short term. The guidance we've issued for this year points to a 38% margin, which represents 120 basis points of improvement over the prior year. Several things are fueling that improvement: robust revenue and a favorable revenue mix in our business, plus ongoing, disciplined yet targeted spending inside our operations. Looking ahead across the next several years, margin gains will come from the $1.5 billion in productivity we anticipate delivering through the spin. We're making solid progress on that front, with $500 million baked into 2021. Over time, the genuine driver of operating margin strength for Merck will mainly be the growth prospects tied to our oncology and vaccines assets; beyond that, you'll continue to see us invest in the business, yet we have confidence in reaching 42%. As you mentioned, there's also a favorable step-down in the royalty rate for KEYTRUDA and, in fact, GARDASIL. That tailwind will assist us in getting to 42%, and our confidence there is strong. Regarding product mix going forward, our company has been disciplined and targeted in the business development deals we pursue. Peloton is a perfect illustration, since it gives us the chance to develop belzutifan, affect our company's top line and therefore its bottom line, and also help the patients we serve. On your last point about REMICADE and SIMPONI, those really aren't a significant factor in that bottom-line growth.
Peter Dannenbaum
executiveDean, Rob, anything else to add before?
Robert M. Davis
executivePerhaps I'll begin, and after that I'll hand things over to Dean. When you consider the possibilities, I genuinely believe that during the period spanning 2024 to 2025, additional details will emerge. The clearest illustration available is the situation with Peloton. More recently, we are already witnessing HIF-2α advance in significant ways. A great deal of data is being generated from that, and we regard it as a substantial opportunity. Perhaps I'll pass it to Dean to provide some perspective, since I truly think you will encounter further information once we reach the window you're referring to, coming from numerous of these business development deals, because of the character of many of the oncology assets.
Dean Li
executiveAppreciate that inquiry. I'll approach it from a broader perspective first, then get to the timing aspect you raised. Regarding the kinds of possibilities we pursue, whether from our own internal pipeline or from outside sources, what we favor — or what I personally favor — are assets offering concentration leverage. Foundational drugs where obvious monotherapy effectiveness provides a pivot point for combining. Particularly when it comes to cancer, that lets us broaden, intensify, and prolong. We seek out such foundational medicines, and the conversations held recently with Gilead and Pandion simply illustrate that mindset about how we intend to move forward, whereby we take foundational medicines and pair them with pipelines both internal and external so we can diversify what's in development. As for what you specifically asked, I'd view the 2021 to 2024 span as containing a whole array of Lynparza, Lenvima, Keytruda studies you're going to be seeing, with much of it pushing toward adjuvant and earlier stages. My count is no fewer than 20 registrational trials. I outlined perhaps four or so that will appear over the coming year. On the business development side, what you're going to observe during the 2024, 2025 period are items such as Uzivarat, VelosBio, Seagen, plus CTLA-4 LAG-3, TIGIT — every one of them will be within striking distance not merely of phase II studies, but possibly interim analysis or even full analysis for those assets during that window. You'll witness the various waves rolling through.
Peter Dannenbaum
executiveThanks, everyone. It's exactly the hour now. We're grateful for this morning's questions and the conversation, and we're eager for any follow-ups over the next few days. Many thanks to all of you.
Operator
operatorAppreciate it, sir. Many thanks as well to the presenters. And once more, thanks to each of you for joining us. That brings today's call to a close. You're welcome to hang up now. Keep well, and enjoy the rest of your day.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Merck & Co., Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Merck & Co., Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Merck & Co., Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.